DFDong Fan

Dong Fan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dong Fan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Huadong Zhao

    Department of General Surgery, Tangdu Hospital, Air Force Medical University, China

    2 shared publications
  • Yuan Gao

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, Air Force Medical University, Xi’an, People’s Republic of China

    2 shared publications
  • Chao Dong

    The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Department of Breast and Thyroid Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, People’s Republic of China

    1 shared publication
  • Chihua Wu

    Department of Breast Surgery, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    1 shared publication
  • Guodong Li

    College of Life Sciences, Northwest University, Xi’an 710069, China

    1 shared publication
  • Lisiyao You

    College of Life Sciences, Northwest University, Xi’an 710069, China

    1 shared publication

Latest Publications

  • Open Access

    Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis

    by Yunpeng Liu, Wei He, Xiaoju Li, Xiyan Lu, Chihua Wu, Yuan Gao, Dong Fan, Chao Dong, Huadong Zhao

    Breast cancer is the most prevalent malignancy worldwide, with approximately 50% of HER2-positive advanced breast cancer patients eventually developing brain metastases, significantly reducing survival. Current HER2-targeted therapies, such as trastuzumab, exhibit limited efficacy in patients with brain metastases due to poor blood-brain barrier penetration and drug resistance. This study aimed to develop a novel strategy for treating HER2-positive breast cancer brain metastases to improve overall survival. We engineered nanoparticles encapsulating circular RNA encoding the chemokine CXCL9 and an anti-PD-1 scFv, designed to target HER2-positive brain metastases. Our results demonstrate that these nanoparticles significantly enhance anti-tumor activity both in vitro and in vivo without exhibiting significant systemic toxicity. This approach improves the local tumor immune microenvironment while inducing lower systemic toxicity. In conclusion, we have established a platform of membrane-encapsulated circular RNA nanoparticles capable of targeting brain tumor lesions, showing potential for application in various brain disorders, including metastatic brain tumors. This novel approach offers a promising strategy for addressing the urgent need for effective treatments for HER2-positive breast cancer brain metastases.


  • Open Access

    Diverse nanoparticles deliver mRNA to enhance tumor immunotherapy

    by Wei He, Meng Zhang, Yuexia Zhong, Yuan Gao, Dong Fan, Xiyan Lu

    Wei He, Meng Zhang, Yuexia Zhong, Yuan Gao, Dong Fan, Xiyan Lu. BMB Reports -0001;0:. https://doi.org/10.5483/BMBRep.2024-0165


  • Open Access

    Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy

    by Guodong Li, Shuangpeng Pu, Lisiyao You, Yuan Gao, Yuexia Zhong, Huadong Zhao, Dong Fan, Xiyan Lu

    Outer membrane vesicles (OMVs) are double-layered structures of nanoscale lipids released by gram-negative bacteria. They have the same membrane composition and characteristics as primitive cells, which enables them to penetrate cells and tissues efficiently. These OMVs exhibit excellent membrane stability, immunogenicity, safety, and permeability (which makes it easier for them to penetrate into tumour tissue), making them suitable for developing cancer vaccines and drug delivery systems. Recent studies have focused on engineering OMVs to enhance tumour-targeting capabilities, reduce toxicity, and extend circulation time in vivo. This article reviews the latest progress in OMV engineering for tumour treatment and discusses the challenges associated with the use of OMV-based antitumour therapy in clinical practice.